Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- National Cancer Institute, Slovakia
- Registration Number
- NCT04265274
- Locations
- 🇸🇰
National Cancer Institute, Bratislava, Slovakia
Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- International Group of Endovascular Oncology
- Target Recruit Count
- 40
- Registration Number
- NCT04208854
- Locations
- 🇮🇹
Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Yes, Italy
Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 200
- Registration Number
- NCT04143906
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 34
- Registration Number
- NCT04145349
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 256
- Registration Number
- NCT03997539
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 543
- Registration Number
- NCT03901339
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Maryland Oncology Hematology, P.A., Rockville, Maryland, United States
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Helix BioPharma Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT03891173
- Locations
- 🇺🇦
Vinnytsya Regional Clinical Oncological Centre, Vinnytsia, Ukraine
🇵🇱Europejskie Centrum Zdrowia Otwock, Otwock, Poland
🇺🇦Sumy Regional Clinical Oncological Centre, Sumy, Ukraine
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- iOMEDICO AG
- Registration Number
- NCT03811418
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany
Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 80
- Registration Number
- NCT03801304
- Locations
- 🇫🇷
CH Aix en Provence, Aix-en-Provence, France
🇫🇷CLCC Caen, Caen, France
🇫🇷CH de Créteil, Créteil, France
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03770299
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.